Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics (Nasdaq: SABS) is a clinical-stage biopharmaceutical leader advancing novel immunotherapies through its DiversitAb platform. This page provides investors and industry professionals with timely updates on clinical developments, financial announcements, and strategic initiatives.
Access official press releases, trial milestones, and partnership announcements in one centralized hub. Our curated news collection covers critical updates including FDA communications, research breakthroughs, and quarterly earnings reports—all essential for tracking SABS's progress in treating type 1 diabetes and autoimmune disorders.
Discover how SAB BIO's transchromosomic cattle technology enables rapid production of fully human antibodies, with updates on lead candidate SAB-142 and pipeline expansion. Bookmark this page for direct access to verified information supporting data-driven investment and research decisions.
SAB BIO (SABS) announced its Q4 and full-year 2024 financial results, highlighting positive topline data from Phase 1 trials of SAB-142, their human anti-thymocyte immunoglobulin therapy for Type 1 Diabetes. The study met primary objectives for safety and pharmacodynamic activity, paving the way for Phase 2b trials expected mid-2025.
Financial highlights for FY2024 include:
- Cash position of $20.8M (down from $56.6M in 2023)
- R&D expenses increased to $30.3M (from $16.5M in 2023)
- G&A expenses decreased to $14.0M (from $23.8M in 2023)
- Net loss improved to $34.1M (from $42.2M in 2023)
- Other net income of $8.8M (compared to $4.1M expense in 2023)
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing SAB-142, has announced its participation in two upcoming investor conferences. The company, which focuses on a novel immunotherapy platform for potentially delaying type 1 diabetes onset or progression, will be present at:
1. The Guggenheim SMID Cap Biotech Conference on February 6, 2025, featuring a fireside chat from 2:00 – 2:25pm ET
2. The Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, delivering a company presentation from 10:00 – 10:30am ET
Both events will be accessible via live webcasts and archived recordings through the company's investor relations website.
SAB BIO (SABS) announced positive topline data from its Phase 1 trial of SAB-142, a potential therapy for type 1 diabetes (T1D). The trial met its primary objectives for safety and pharmacodynamic activity in healthy volunteers. Key findings include:
- Favorable safety profile with doses ranging from 0.03mg/kg to 2.5mg/kg
- No reported serum sickness or anti-drug antibodies
- Demonstrated sustained immunomodulation
- Mechanism of action analogous to rabbit ATG
The company plans to advance SAB-142 into Phase 2b clinical development in 2025, targeting adult and pediatric patients with new-onset T1D. The therapy aims to be the first fully human biologic enabling outpatient dosing to delay T1D onset or progression.
SAB BIO (NASDAQ: SABS) has announced a Research and Development webinar scheduled for January 28, 2025, at 8:00 AM EST to discuss topline data from the Phase 1 clinical trial of its lead candidate, SAB-142. The therapy is being developed as a potential disease-modifying treatment for type 1 diabetes (T1D), utilizing the company's novel immunotherapy platform that develops human anti-thymocyte immunoglobulin (hIgG).
The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader Dr. Michael Haller, who serves as the division chief of Pediatric Endocrinology at the University of Florida. A live Q&A session will follow the presentations, and a replay will be available on the company's website.
SAB BIO (SABS) reported Q3 2024 financial results and provided updates on its SAB-142 Type 1 diabetes program. The company completed Phase 1 enrollment with no observed serum sickness and remains on track for topline data readout by year-end. Cash position stood at $30.4 million as of September 30, 2024. Q3 net loss widened to $10.3 million ($1.12 per share) from $5.1 million ($0.97 per share) year-over-year. R&D expenses increased to $7.8 million from $4.0 million, while G&A expenses rose to $3.5 million from $2.6 million in Q3 2023.
SAB BIO (Nasdaq: SABS) announced that Chairman and CEO Samuel J. Reich will participate in a fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference. The event will take place on November 11, 2024, at 3:00pm EST in Boston, MA. SAB BIO is a clinical-stage biopharmaceutical company developing a novel human anti-thymocyte immunoglobulin (hIgG) therapy aimed at delaying the onset or progression of type 1 diabetes. The fireside chat will be accessible via webcast, with a recording available through the company's website events section.
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, announced that its Chairman and CEO, Samuel J. Reich, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference. The event is scheduled for September 18th, 2024, at 8:00 am ET in New York, NY.
SAB BIO is developing a novel immunotherapy platform focusing on a human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of Type 1 Diabetes (T1D). The company has provided a webcast registration link for those interested in attending virtually. Additionally, a recording of the webcast will be available through the 'Events' section of SAB BIO's investor relations website.
SAB BIO (Nasdaq: SABS) has provided an update on its SAB-142 clinical trial at the European Association for the Study of Diabetes Annual Meeting. The company has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is now enrolling patients with type 1 diabetes in the last cohort. Notably, the target dose of 2.5mg/kg was completed with no observation of serum sickness.
SAB-142, a first-in-class human anti-thymocyte immunoglobulin, is being developed to delay the onset and progression of type 1 diabetes. The Phase 1 trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. The company remains on track for a topline Phase 1 data readout by the end of the year.
SAB BIO (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced its participation in the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024, in Madrid. The company's Executive Vice President and Chief Medical Officer, Alexandra Kropotova, MD, MBA, will present on the topic 'Protecting pancreatic beta cells with multi-target, multi-epitope immunotherapy: SAB-142'.
SAB BIO is developing a novel immunotherapy platform using human anti-thymocyte immunoglobulin (hIgG) to delay the onset or progression of type 1 diabetes (T1D). The presentation will take place during the INNODIA EASD Symposium at 8:45 am in the Beijing Hall of the EASD Symposium, highlighting the company's innovative approach to T1D treatment.
SAB BIO (Nasdaq: SABS) reported its Q2 2024 financial results and provided company updates. Key highlights include:
1. FDA clearance for SAB-142 IND application
2. Appointment of Lucy To as CFO
3. Founding of a new Clinical Advisory Board
4. Cash position of $37.3 million as of June 30, 2024
5. R&D expenses increased to $6.8 million in Q2 2024
6. Net loss of $7.3 million for Q2 2024
The company reaffirmed its cash runway into 2026 and remains focused on developing SAB-142 for delaying or stopping the progression of type 1 diabetes. SAB-142 is on track for a topline Phase 1 data readout by year-end.
